Pleiotropic functions of plasminogen activator inhibitor-1. (Q33984228)

30 July 2017

1 reference

title

Pleiotropic functions of plasminogen activator inhibitor-1. (English)

1 reference

30 July 2017

1 reference

1 reference

Lijnen HR

1 reference

30 July 2017

publication date

1 January 2005

1 reference

Journal of Thrombosis and Haemostasis

30 July 2017

published in

1 reference

30 July 2017

1 reference

30 July 2017

1 reference

30 July 2017

page(s)

35-45

1 reference

Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Regulation of the PAI-1 promoter by circadian clock components: differential activation by BMAL1 and BMAL2

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Questioning a class effect: does ACE inhibitor tissue penetration influence the degree of fibrinolytic balance alteration following an acute myocardial infarction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Serotonin 5-HT2a and 5-HT2c receptors stimulate amyloid precursor protein ectodomain secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Structural basis of latency in plasminogen activator inhibitor-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

The reactive-center loop of active PAI-1 is folded close to the protein core and can be partially inserted

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

The urokinase plasminogen activator receptor in the regulation of the actin cytoskeleton and cell motility

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Kinetic analysis of the interaction between vitronectin and the urokinase receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Induction of Apoptosis in Vascular Cells by Plasminogen Activator Inhibitor-1 and High Molecular Weight Kininogen Correlates with Their Anti-Adhesive Properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Increased expression of plasminogen activator inhibitor-1 in cardiomyocytes contributes to cardiac fibrosis after myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Endogenous tissue-type plasminogen activator and risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

The plasminogen activator inhibitor-1 -675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

A critical review of the relationship between impaired fibrinolysis and myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Remodeling of the vessel wall after copper-induced injury is highly attenuated in mice with a total deficiency of plasminogen activator inhibitor-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Plasminogen activator inhibitor type 1 enhances neointima formation after oxidative vascular injury in atherosclerosis-prone mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Accelerated skin wound healing in plasminogen activator inhibitor-1-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Plasminogen activator inhibitor type-1 inhibits insulin signaling by competing with alphavbeta3 integrin for vitronectin binding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Divergent roles for p55 and p75 TNF-alpha receptors in the induction of plasminogen activator inhibitor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Nutritionally induced obesity is attenuated in transgenic mice overexpressing plasminogen activator inhibitor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Mouse aortic ring assay: A new approach of the molecular genetics of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Relationship between job stress and plasma fibrinolytic activity in male Japanese workers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Plasminogen activator inhibitor-1 is a major stress-regulated gene: implications for stress-induced thrombosis in aged individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Reduction in fibrotic tissue formation in mice genetically deficient in plasminogen activator inhibitor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Fibrinolysis in LPS-induced chronic airway disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

PAI-1 in human hypertension: relation to hypertensive groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Plasminogen activator inhibitor-1 is a significant determinant of renal injury in experimental crescentic glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Five Frequent Polymorphisms of the PAI-1 Gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2004.00827.X

10.1111/J.1538-7836.2004.00827.X

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference